{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:38:28Z","timestamp":1778683108371,"version":"3.51.4"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Oral fluid (OF) is increasingly used as an alternative sample matrix in drug of abuse screening. Screening is commonly performed by immunoassays and results confirmed using laborious gas chromatography\u2013mass spectrometry (GC-MS)\u2013based methods. Therefore, an easy to operate ion trap mass spectrometric (IT-MS) commercial screening method (Toxtyper; Bruker Daltronik, Bremen, Germany) combined with a laboratory-developed sample preparation procedure has been evaluated for their application to OF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>OF samples were subjected to protein precipitation followed by HybridSPE-Phospholipid extraction. Chromatographic separation was achieved by ultra\u2013high-performance liquid chromatography; MS2\/MS3 spectra were recorded by IT-MS and analyzed using a library provided by the manufacturer (Bruker Daltronik). The lower limit of detection, linearity, imprecision, inaccuracy, and specificity (interferences and matrix effects) were investigated for methadone, buprenorphine, pregabalin, fentanyl, amphetamine, 3,4-methylendioxy-N-methylamphetamine, cocaine, acetylcodeine, and nordiazepam, after spiking drug-free OF with these test substances. In addition, concordance between IT-MS results and gas chromatography\u2013tandem mass spectrometry, liquid chromatography\u2013tandem mass spectrometry, or immunoassay (buprenorphine) results was investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>No interferences or matrix effects were observed. The lower limit of detection for acetylcodeine, amphetamine, benzoylecgonine, methadone, and nordiazepam was below the common cutoffs for immunological screening assays and comparable to that of GC-MS. Imprecision and inaccuracy, both in- and between-series, were consistently &lt;25%, except for buprenorphine. Toxtyper screening for pregabalin and fentanyl was less sensitive than a targeted liquid chromatography\u2013tandem mass spectrometry assay. A very good concordance was found between the previous analytical approach and the new IT-MS method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The Toxtyper IT-MS is easy to use and can be applied for the screening of drug of abuse and the qualitative confirmation analysis in OF in a clinical toxicology service. Although intended for qualitative analysis, performance data suggest that the methods investigated may also be applicable for semiquantitative longitudinal follow-up.<\/jats:p><\/jats:sec>","DOI":"10.1097\/ftd.0000000000000544","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T22:11:05Z","timestamp":1528409465000},"page":"642-648","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of an Ion Trap Toxtyper Liquid Chromatography With An Ion Trap Mass Spectrometric Instrument (Toxtyper) for Drug of Abuse Screening in Oral Fluid"],"prefix":"10.1097","volume":"40","author":[{"given":"Thomas","family":"Plecko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Berbalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Wieland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Shipkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.drugalcdep.2006.08.020","article-title":"Oral fluid as an alternative matrix to monitor opiate and cocaine use in substance-abuse treatment patients","volume":"87","author":"Dams","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/dta.1532","article-title":"Comparison of drug concentrations between whole blood and oral fluid","volume":"6","author":"Langel","year":"2014","journal-title":"Drug Test Anal."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.forsciint.2015.06.027","article-title":"Detection of illicit drugs in oral fluid from drivers as biomarker for drugs in blood","volume":"256","author":"Gjerde","year":"2015","journal-title":"Forensic Sci Int."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1373\/clinchem.2008.108670","article-title":"Oral fluid testing for drugs of abuse","volume":"55","author":"Bosker","year":"2009","journal-title":"Clin Chem."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jsat.2017.01.005","article-title":"Urine drug testing results and paired oral fluid comparison from patients enrolled in long-term medication-assisted treatment in Tennessee","volume":"76","author":"Miller","year":"2017","journal-title":"J Subst Abuse Treat."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.trac.2016.07.010","article-title":"Saliva as an alternative specimen to plasma for drug bioanalysis: a review","volume":"83","author":"Elmongy","year":"2016","journal-title":"Trends Analyt Chem."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.forsciint.2004.10.026","article-title":"Review: the physiology of saliva and transfer of drugs into saliva","volume":"150","author":"Aps","year":"2005","journal-title":"Forensic Sci Int."},{"key":"R8-20230814","first-page":"147","article-title":"Drug testing in oral fluid","volume":"27","author":"Drummer","year":"2006","journal-title":"Clin Biochem Rev."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/jat\/bkv123","article-title":"Influence of sampling procedure on codeine concentrations in oral fluid","volume":"40","author":"Coucke","year":"2016","journal-title":"J Anal Toxicol."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.forsciint.2016.01.013","article-title":"Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration","volume":"260","author":"Ellefsen","year":"2016","journal-title":"Forensic Sci Int."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1016\/j.jchromb.2011.07.029","article-title":"Online extraction LC-MS\/MS method for the simultaneous quantitative confirmation of urine drugs of abuse and metabolites: amphetamines, opiates, cocaine, cannabis, benzodiazepines and methadone","volume":"25","author":"de Jager","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jchromb.2013.12.014","article-title":"Screening and quantitative determination of drugs of abuse in diluted urine by UPLC-MS\/MS","volume":"947\u2013948","author":"Hegstad","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clinms.2017.08.002","article-title":"Detection of drugs of abuse in urine using the Bruker ToxtyperTM: experiences in a routine clinical laboratory setting","volume":"4\u20135","author":"Ott","year":"2017","journal-title":"Clin Mass Spectrom."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jchromb.2011.02.027","article-title":"A validated method for the detection and quantitation of 50 drugs of abuse and medicinal drugs in oral fluid by gas chromatography-mass spectrometry","volume":"879","author":"Langel","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.forc.2017.03.002","article-title":"Rapid confirmation and quantitation of drugs-of-abuse in oral fluid using a low cost, small footprint mass spectrometer","volume":"4","author":"Schepens","year":"2017","journal-title":"Forensic Chem."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jat\/26.8.541","article-title":"Oral fluid testing for drugs of abuse: positive prevalence rates by intercept TM immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations","volume":"25","author":"Cone","year":"2002","journal-title":"J Anal Toxicol."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s007690050234","article-title":"Limits of detection, identification and determination: a statistical approach for practitioners","volume":"3","author":"Vogelsang","year":"1988","journal-title":"Accred Qual Assur."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1007\/s00216-011-5032-1","article-title":"Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept","volume":"400","author":"Wissenbach","year":"2011","journal-title":"Anal Bioanal Chem."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/dta.2229","article-title":"European guidelines for workplace drug testing in oral fluid","volume":"10","author":"Brcak","year":"2018","journal-title":"Drug Test Anal."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201810000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T10:20:15Z","timestamp":1720347615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201810000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000544","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}